Skip to main content
Top
Published in: AIDS and Behavior 12/2016

01-12-2016 | Original Paper

Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting

Authors: Stephanie Lake, Thomas Kerr, Jane Buxton, Silvia Guillemi, Surita Parashar, Julio Montaner, Evan Wood, M.-J. Milloy

Published in: AIDS and Behavior | Issue 12/2016

Login to get access

Abstract

Prescription opioids (POs) are commonly prescribed to patients living with HIV/AIDS, while the illicit use of POs remains a major public health concern throughout Canada and the United States. We sought to identify the prevalence and correlates of PO injection among HIV-positive people who inject drugs (PWID) in Vancouver, Canada, where HIV/AIDS treatment and care is offered at no cost. We examined data from 634 individuals from an ongoing prospective cohort of HIV-positive PWID. Between December 2005 and November 2013, the median prevalence of recent PO injection was 24.2 % [interquartile range (IQR): 21.5–25.8 %]. In a multivariable generalized estimating equation model, Caucasian ethnicity, heroin injection, and drug dealing were positively associated with PO injection, while older age and methadone maintenance treatment were negatively associated with PO injection (all p < 0.05). Engagement on antiretroviral therapy was inversely associated with PO injection in a bivariable analysis, but did not remain significant after adjusting for heroin injection. These findings describe a particularly vulnerable sub-group of PWID who may benefit from targeted efforts to both minimize drug-related risk behaviors and support HIV/AIDS treatment.
Literature
1.
go back to reference Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75.CrossRefPubMedPubMedCentral Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75.CrossRefPubMedPubMedCentral
2.
go back to reference Edlund MJ, Martin BC, Devries A, Fan M-Y, Braden JB, Sullivan MD. Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010;26(1):1–8.CrossRefPubMedPubMedCentral Edlund MJ, Martin BC, Devries A, Fan M-Y, Braden JB, Sullivan MD. Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010;26(1):1–8.CrossRefPubMedPubMedCentral
3.
go back to reference Sullivan MD, Edlund MJ, Fan M-Y, DeVries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440–9.CrossRefPubMedPubMedCentral Sullivan MD, Edlund MJ, Fan M-Y, DeVries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440–9.CrossRefPubMedPubMedCentral
4.
go back to reference Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–8.CrossRefPubMed Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–8.CrossRefPubMed
5.
go back to reference Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005–2009. Pharmacoepidemiol Drug Saf. 2013;22(4):438–42.CrossRefPubMed Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005–2009. Pharmacoepidemiol Drug Saf. 2013;22(4):438–42.CrossRefPubMed
6.
go back to reference Centers for Disease Control and Prevention. Prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3. Centers for Disease Control and Prevention. Prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.
7.
go back to reference Suryaprasad AG, White JZ, Xu FJ, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Inf Dis. 2014;59(10):1411–9.CrossRef Suryaprasad AG, White JZ, Xu FJ, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Inf Dis. 2014;59(10):1411–9.CrossRef
8.
go back to reference Zibbell JE, Hart-Malloy R, Barry JL, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104(11):2226–32.CrossRefPubMedPubMedCentral Zibbell JE, Hart-Malloy R, Barry JL, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104(11):2226–32.CrossRefPubMedPubMedCentral
9.
go back to reference Centers for Disease Control and Prevention. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4. Centers for Disease Control and Prevention. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.
10.
go back to reference Leclerc P, Roy E, Morissette C, Michel A, Parent R, SurvUDI Working Group, editors. Extent and correlates of injection of prescription opioids for non-medical purposes in the SurvUDI network. 20th Annual Canadian Conference on HIV/AIDS Research. Toronto; 2011. Leclerc P, Roy E, Morissette C, Michel A, Parent R, SurvUDI Working Group, editors. Extent and correlates of injection of prescription opioids for non-medical purposes in the SurvUDI network. 20th Annual Canadian Conference on HIV/AIDS Research. Toronto; 2011.
11.
go back to reference Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS, Wood E. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open. 2014;4(7):e005419.CrossRefPubMedPubMedCentral Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS, Wood E. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open. 2014;4(7):e005419.CrossRefPubMedPubMedCentral
13.
go back to reference Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318–27.CrossRefPubMed Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318–27.CrossRefPubMed
15.
go back to reference Montaner J, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.CrossRefPubMedPubMedCentral Montaner J, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.CrossRefPubMedPubMedCentral
16.
go back to reference Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.CrossRefPubMedPubMedCentral Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.CrossRefPubMedPubMedCentral
17.
go back to reference Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One. 2010;5(6):e10991.CrossRefPubMedPubMedCentral Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One. 2010;5(6):e10991.CrossRefPubMedPubMedCentral
18.
go back to reference Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Inf Dis. 2011;11(7):516–24.CrossRef Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Inf Dis. 2011;11(7):516–24.CrossRef
19.
go back to reference Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21(1):4–9.CrossRefPubMed Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21(1):4–9.CrossRefPubMed
21.
go back to reference Strathdee S, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–9.CrossRefPubMed Strathdee S, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–9.CrossRefPubMed
22.
go back to reference Nolan S, Milloy MJ, Zhang R, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care. 2011;23(8):980–7.CrossRefPubMed Nolan S, Milloy MJ, Zhang R, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care. 2011;23(8):980–7.CrossRefPubMed
23.
go back to reference Linden IA, Mar MY, Werker GR, Jang K, Krausz M. Research on a vulnerable neighborhood—the Vancouver Downtown Eastside from 2001 to 2011. J Urban Health. 2013;90(3):559–73.CrossRefPubMed Linden IA, Mar MY, Werker GR, Jang K, Krausz M. Research on a vulnerable neighborhood—the Vancouver Downtown Eastside from 2001 to 2011. J Urban Health. 2013;90(3):559–73.CrossRefPubMed
24.
go back to reference Kerr T, Marshall BD, Milloy MJ, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend. 2012;124(1–2):108–12.CrossRefPubMedPubMedCentral Kerr T, Marshall BD, Milloy MJ, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend. 2012;124(1–2):108–12.CrossRefPubMedPubMedCentral
25.
go back to reference Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.CrossRefPubMed Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.CrossRefPubMed
26.
go back to reference Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.CrossRefPubMedPubMedCentral Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.CrossRefPubMedPubMedCentral
27.
go back to reference Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.CrossRefPubMed Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.CrossRefPubMed
28.
go back to reference Lee JH, Herzog TA, Meade CD, Webb MS, Brandon TH. The use of GEE for analyzing longitudinal binomial data: a primer using data from a tobacco intervention. Addict Behav. 2007;32(1):187–93.CrossRefPubMed Lee JH, Herzog TA, Meade CD, Webb MS, Brandon TH. The use of GEE for analyzing longitudinal binomial data: a primer using data from a tobacco intervention. Addict Behav. 2007;32(1):187–93.CrossRefPubMed
31.
go back to reference Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008;27(6):625–32.CrossRefPubMed Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008;27(6):625–32.CrossRefPubMed
32.
go back to reference Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90(1):64–71.CrossRefPubMed Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90(1):64–71.CrossRefPubMed
33.
go back to reference Lankenau SE, Schrager SM, Silva K, et al. Misuse of prescription and illicit drugs among high-risk young adults in Los Angeles and New York. J Public Health Res. 2012;1(1):22–30.CrossRefPubMedPubMedCentral Lankenau SE, Schrager SM, Silva K, et al. Misuse of prescription and illicit drugs among high-risk young adults in Los Angeles and New York. J Public Health Res. 2012;1(1):22–30.CrossRefPubMedPubMedCentral
34.
go back to reference Brands B, Blake J, Sproule B, Gourlay D, Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199–207.CrossRefPubMed Brands B, Blake J, Sproule B, Gourlay D, Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199–207.CrossRefPubMed
35.
go back to reference Degenhardt L, Black E, Breen C, et al. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev. 2006;25(5):403–12.CrossRefPubMed Degenhardt L, Black E, Breen C, et al. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev. 2006;25(5):403–12.CrossRefPubMed
36.
go back to reference Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs. 2015;22(1):35–42.PubMedPubMedCentral Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs. 2015;22(1):35–42.PubMedPubMedCentral
37.
go back to reference Lake S, Hayashi K, Buxton J, et al. The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs. Drug Alcohol Depend. 2015;156:297–303.CrossRefPubMedPubMedCentral Lake S, Hayashi K, Buxton J, et al. The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs. Drug Alcohol Depend. 2015;156:297–303.CrossRefPubMedPubMedCentral
38.
go back to reference Roy E, Arruda N, Vaillancourt E, et al. Drug use patterns in the presence of crack in downtown Montréal. Drug Alcohol Rev. 2012;31(1):72–80.CrossRefPubMed Roy E, Arruda N, Vaillancourt E, et al. Drug use patterns in the presence of crack in downtown Montréal. Drug Alcohol Rev. 2012;31(1):72–80.CrossRefPubMed
39.
go back to reference Darke S, Williamson A, Ross J, Teesson M. Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24(5):425–32.CrossRefPubMed Darke S, Williamson A, Ross J, Teesson M. Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24(5):425–32.CrossRefPubMed
40.
go back to reference de la Fuente L, Molist G, Espelt A, et al. Mortality risk factors and excess mortality in a cohort of cocaine users admitted to drug treatment in Spain. J Subst Abuse Treat. 2014;46(2):219–26.CrossRefPubMed de la Fuente L, Molist G, Espelt A, et al. Mortality risk factors and excess mortality in a cohort of cocaine users admitted to drug treatment in Spain. J Subst Abuse Treat. 2014;46(2):219–26.CrossRefPubMed
41.
go back to reference Kerr T, Small W, Johnston C, Li K, Montaner JSG, Wood E. Characteristics of injection drug users who participate in drug dealing: implications for drug policy. J Psychoactive Drugs. 2008;40(2):147–52.CrossRefPubMed Kerr T, Small W, Johnston C, Li K, Montaner JSG, Wood E. Characteristics of injection drug users who participate in drug dealing: implications for drug policy. J Psychoactive Drugs. 2008;40(2):147–52.CrossRefPubMed
43.
go back to reference Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW. The “black box” of prescription drug diversion. J Addict Dis. 2009;28(4):332–47.CrossRefPubMedPubMedCentral Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW. The “black box” of prescription drug diversion. J Addict Dis. 2009;28(4):332–47.CrossRefPubMedPubMedCentral
44.
go back to reference Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92(1–3):267–76.CrossRefPubMed Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92(1–3):267–76.CrossRefPubMed
45.
go back to reference Rigg KK, Kurtz SP, Surratt HL. Patterns of prescription medication diversion among drug dealers. Drugs. 2012;19(2):144–55.PubMedPubMedCentral Rigg KK, Kurtz SP, Surratt HL. Patterns of prescription medication diversion among drug dealers. Drugs. 2012;19(2):144–55.PubMedPubMedCentral
46.
go back to reference Jeevanjee S, Penko J, Guzman D, Miaskowski C, Bangsberg DR, Kushel MB. Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco. AIDS Behav. 2014;18(7):1352–8.CrossRefPubMedPubMedCentral Jeevanjee S, Penko J, Guzman D, Miaskowski C, Bangsberg DR, Kushel MB. Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco. AIDS Behav. 2014;18(7):1352–8.CrossRefPubMedPubMedCentral
47.
go back to reference Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Inf Dis. 2007;45(Suppl. 4):S318–23.CrossRef Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Inf Dis. 2007;45(Suppl. 4):S318–23.CrossRef
48.
go back to reference Wood E, Montaner JSG, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656–61.PubMedPubMedCentral Wood E, Montaner JSG, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656–61.PubMedPubMedCentral
49.
go back to reference Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907–13.CrossRefPubMedPubMedCentral Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907–13.CrossRefPubMedPubMedCentral
50.
go back to reference Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.CrossRefPubMed Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.CrossRefPubMed
51.
go back to reference Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5):e38335.CrossRefPubMedPubMedCentral Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5):e38335.CrossRefPubMedPubMedCentral
52.
go back to reference Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Inf Dis. 2009;49(9):1433–40.CrossRef Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Inf Dis. 2009;49(9):1433–40.CrossRef
53.
go back to reference Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.CrossRefPubMed Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.CrossRefPubMed
54.
go back to reference Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.CrossRefPubMed Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.CrossRefPubMed
55.
go back to reference Hammig R, Kohler W, Bonorden-Kleij K, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275–81.CrossRefPubMed Hammig R, Kohler W, Bonorden-Kleij K, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275–81.CrossRefPubMed
56.
go back to reference Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18(4):262–70.CrossRefPubMed Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18(4):262–70.CrossRefPubMed
57.
go back to reference Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–63.CrossRefPubMed Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–63.CrossRefPubMed
Metadata
Title
Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting
Authors
Stephanie Lake
Thomas Kerr
Jane Buxton
Silvia Guillemi
Surita Parashar
Julio Montaner
Evan Wood
M.-J. Milloy
Publication date
01-12-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1369-y

Other articles of this Issue 12/2016

AIDS and Behavior 12/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.